Literature DB >> 19603009

Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma.

Yusuke Okuwaki1, Takahide Nakazawa, Shigehiro Kokubu, Hisashi Hidaka, Yoshiaki Tanaka, Juichi Takada, Masaaki Watanabe, Akitaka Shibuya, Tsutomu Minamino, Katsunori Saigenji.   

Abstract

OBJECTIVES: Intrahepatic distant recurrence (IDR) of hepatocellular carcinoma (HCC) after curative treatment occurs frequently and influences the prognoses. The aim of this study was to determine prognostic factors affecting survival after IDR and the optimum therapy for IDR.
METHODS: A total of 115 patients with a single small primary HCC who had complete radiofrequency (RF) ablation were enrolled in this study. The prognostic factors and the optimum therapy affecting survival were statistically analyzed among patients with IDRs.
RESULTS: IDRs were observed in 59 (51.3%) patients with the median observation period of 19.6 months. The cumulative rates of IDRs were 11.8, 53.9, and 75.8% at 1, 3, and 5 years, respectively. IDR nodules were present as a single nodule in 38 patients and as multiple nodules in 21 patients. In all, 23 patients died during the follow-up. A total of 30 patients were treated with RF ablation, and 27 were treated with transcatheter arterial chemoembolization (TACE). The overall cumulative survival rates after IDRs were 92.7, 55.4, and 43.7% at 1, 3, and 5 years, respectively. A multivariate analysis showed that treatment with RF ablation for IDR was a significant favorable prognostic factor after IDR (hazard ratio: 0.167, 95% confidence interval: 0.048-0.584, P=0.005). In a comparison of survival after IDR between patients treated with RF ablation and TACE, who were comparable with clinical and tumoral characteristics, the cumulative survival rate of patients treated with RF ablation was significantly higher than that of those treated with TACE (77.2 vs 28.5% at 3 years). The cumulative survival rates obtained from the initial RF ablation of the patients with IDRs treated with repeat RF ablation were similar to those of recurrence-free patients.
CONCLUSIONS: Repeat RF ablation should be attempted for IDR as much as possible despite tumor multiplicity for survival benefit; by reducing the need, it will help solve the problem of the current shortage of donors for liver transplantations.

Entities:  

Mesh:

Year:  2009        PMID: 19603009     DOI: 10.1038/ajg.2009.414

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  21 in total

1.  Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report.

Authors:  Yusuke Okuwaki; Takahide Nakazawa; Hisashi Hidaka; Akitaka Shibuya; Wasaburo Koizumi
Journal:  J Med Case Rep       Date:  2012-01-26

2.  Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection.

Authors:  Tsuyoshi Notake; Akira Kobayashi; Hiroji Shinkawa; Takuya Kawahara; Akira Shimizu; Takahide Yokoyama; Kiyoshi Hasegawa; Norihiro Kokudo; Yutaka Matsuyama; Masatoshi Makuuchi; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2017-03-16       Impact factor: 3.402

3.  Recurrent hepatocellular carcinoma successfully treated with laparoscopic thermal ablation.

Authors:  Roberto Santambrogio; Mara Costa; Matteo Barabino; Massimo Zuin; Emanuela Bertolini; Francesca De Filippi; Savino Bruno; Enrico Opocher
Journal:  Surg Endosc       Date:  2011-11-02       Impact factor: 4.584

Review 4.  Local ablation for hepatocellular carcinoma in taiwan.

Authors:  Shi-Ming Lin
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

5.  Repeat treatment for recurrent hepatocellular carcinoma: is it validated?

Authors:  Yoji Kishi; Akio Saiura; Junji Yamamoto; Rintaro Koga; Makoto Seki; Ryo Morimura; Ryuji Yoshioka; Norihiro Kokudo; Toshiharu Yamaguchi
Journal:  Langenbecks Arch Surg       Date:  2011-08-17       Impact factor: 3.445

Review 6.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

Review 7.  Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Tomoo Kosuge
Journal:  World J Hepatol       Date:  2014-12-27

8.  Incidence of new foci of hepatocellular carcinoma after radiofrequency ablation: role of multidetector CT.

Authors:  T V Bartolotta; A Taibbi; D Matranga; L Sandonato; S Asta; M Midiri; R Lagalla
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

9.  Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors.

Authors:  Cheng William Hong; Lucy Chow; Evrim B Turkbey; Riccardo Lencioni; Steven K Libutti; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2015-07-31       Impact factor: 2.740

10.  Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection.

Authors:  Hadrien Tranchart; Mircea Chirica; Ailton Sepulveda; Pierre-Philippe Massault; Filomena Conti; Olivier Scatton; Olivier Soubrane
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.